An observational study in Sepsis and Inflammatory Response, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 123rd largest by planned enrollment of the 164 observational ones that give a count, is one of 18 that started in 2023, is one of 165 observational ones, reaches primary completion later than 44 of the 105 other live ones, and was the 176th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 18 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has 8 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Severe sepsis is the most common cause of death among critically ill patients in non-coronary intensive care units (ICU). Sustained excessive inflammation and immune dysfunction have been confirmed to play a key role in organ damage and early death of sepsis patients. Therefore, it is important to reduce excessive inflammatory response mediated by immune cells and pro-inflammatory cytokines in the acute phase of sepsis.
Single-cell RNA sequencing performed on both septic patients and mice suggest that changes in Tcm (CD3+ CD8+ CD44+ CD127+ CD62L+) and Tem (CD3+ CD8+ CD44+ CD127+ CD62L -) in the acute phase of sepsis may play an important role in sepsis. In addition, animal researches showed that Tcm and Tem decreased decreased continuously at 24, 48 and 72h after cecal ligation and perforation (CLP) in mice, and the adoptive transfer of Tcm , sorting from spleen of mice 24h after CLP , but not Tem improved 7-day survival rate of sepsis mice.
This observational study is aimed to investigate the quantity and proliferation of Tcm and Tem in the acute phase of sepsis and their correlation with severity level and mortality of septic patients in ICU.
patients with sepsis defined based on Sepsis 3.0 criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and/or their family members know and agree to participate in the trial.
Exclusion Criteria:
History of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as diseases such as rheumatoid arthritis and SLE, or hematological such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and/or their family members refuse to participate in the trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission
healthy adults
Absolute number of CD8+T subsets in the peripheral blood (0 hour)
CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells
Time frame: 0 hour after study inclusion
Absolute number of CD8+T subsets in the peripheral blood (24 hours)
CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells
Time frame: 24 hours after study inclusion
Absolute number of CD8+T subsets in the peripheral blood (48 hours)
CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells
Time frame: 48 hours after study inclusion
Absolute number of CD8+T subsets in the peripheral blood (72 hours)
CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells
Time frame: 72 hours after study inclusion
proliferation of CD8+T subsets in the peripheral blood (0 hour)
expression of Ki67 in Tcm and Tem
Time frame: 0 hour after study inclusion
proliferation of CD8+T subsets in the peripheral blood (24 hours)
expression of Ki67 in Tcm and Tem
Time frame: 24 hours after study inclusion
proliferation of CD8+T subsets in the peripheral blood (48 hours)
expression of Ki67 in Tcm and Tem
Time frame: 48 hours after study inclusion
proliferation of CD8+T subsets in the peripheral blood (72 hours)
expression of Ki67 in Tcm and Tem
Time frame: 72 hours after study inclusion
ICU length of stay
Length of stay in the ICU
Time frame: up to 4 weeks
PD-1 expression of CD8+T subsets in the peripheral blood (24 hours)
expression of PD-1 in Tcm and Tem
Time frame: 24 hours after study inclusion
Mechanical ventilation time after inclusion
Patients requiring mechanical ventilation after study inclusion
Time frame: up to 4 weeks
Total hospital length of stay
Total length of hospital stay
Time frame: up to 4 weeks
In-hospital mortality
Mortality rates for the entire period of hospitalization
Time frame: up to 4 weeks
90-day readmission rate
Percentage of readmission to hospital within 90 days of study inclusion
Time frame: up to 4 weeks
Infection complications
Pulmonary infection, urinary tract infection, bloodstream infections, etc
Time frame: up to 4 weeks
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 0h after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 24 hours after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 48 hours after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 72 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 0 hour after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 24 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 48 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 72 hours after study inclusion
Plasma cytokine levels
IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α
Time frame: 0 hour after study inclusion
Plasma cytokine levels
IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α
Time frame: 24 hours after study inclusion
Plasma cytokine levels
IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α
Time frame: 48 hours after study inclusion
Plasma cytokine levels
IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α
Time frame: 72 hours after study inclusion
Peripheral blood PMN-MDSC levels
Frequencies and absolute numbers of total PMN-MDSCs (CD45⁺ CD11b⁺ CD15⁺ CD14- CD33⁺ HLA-DRˡᵒʷ) and the CXCR2⁺ PD-L1⁺ PMN-MDSC subpopulation, assessed via flow cytometry.
Time frame: Within 72 hours of sepsis diagnosis or ICU admission.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Oct 2026, 37 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 37 months is above that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Oct 2026 and completion Sep 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →